RELFF yields 57.14% · JNJ yields 2.14%● Live data
📍 RELFF pulled ahead of the other in Year 1
Combined, RELFF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RELFF + JNJ for your $10,000?
Reliance Infrastructure Limited, an infrastructure company, generates, transmits, and distributes electrical power to residential, industrial, commercial, and other consumers in India. It operates through three segments: Power; Engineering and Construction (E&C); and Infrastructure. The Power segment operates a 220 MW combined cycle power plant at Samalkot; 48 MW combined cycle power plant at Mormugao; and 9.39 MW wind farm at Chitradurga. This segment also distribute power in Delhi; operates a 165 MW combined cycle power plant at Kochi; transmits power through its transmission networks in the states of Himachal Pradesh; and trades in power. The E&C segment offers value added services in construction, erection, commissioning, and contracting. The Infrastructure segment engages in the development, operation, and maintenance of toll roads, metro rail transit system, and airports. The company is involved in the exploration and production of 4 coal bed methane blocks covering an area of 3,266 square kilometers in Madhya Pradesh, Andhra Pradesh, and Rajasthan; an oil and gas block covering an area of 3,619 square kilometers in Mizoram; and rehabilitation and upgradation of NH-66. In addition, it manufactures cement and defense systems; constructs smart city projects; and develops real estate and urban transport systems. Reliance Infrastructure Limited was incorporated in 1929 and is based in Mumbai, India.
Full RELFF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.